問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Dermatology

Division of Rheumatology

更新時間：2023-09-19

陳彥如
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

27Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳彥如

List

41Cases

2026-05-31 - 2030-06-30

Phase III

Not yet recruiting
A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial evaluating the efficacy, safety, and tolerability of cenerimod in combination with background therapy in adult patients with systemic lupus erythematosus and active lupus nephritis.

  • Condition/Disease

    Nephritis and nephropathy not specified as acute or chronic, classified elsewhere | Systemic lupus erythematosus

  • Test Drug

    Cenerimod

Participate Sites
9Sites

Not yet recruiting9Sites

2021-10-01 - 2023-12-31

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2026-03-31 - 2028-12-31

Phase I

Active
A Phase 1, open-label, dose-escalation study (ELEVATE-1) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven autoimmune rheumatic diseases (ARD)

  • Condition/Disease

    Sacroiliac Joint Pain

  • Test Drug

    GSK5926371

Participate Sites
3Sites

Recruiting3Sites

2023-06-03 - 2027-09-04

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Not yet recruiting2Sites

2023-12-01 - 2026-12-28

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Not yet recruiting2Sites

2023-12-26 - 2026-05-14

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-12-01 - 2027-11-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2025-11-15 - 2030-03-31

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2019-10-31 - 2023-10-05

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-07-14 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB